在急性冠状动脉综合征的精准医学
Andrea Caffè1, Francesco Maria Animati1, Giulia Iannaccone1
1Department of Cardiovascular and Pulmonary Sciences, Catholic University of the Sacred Heart, 00168 Rome, Italy.
目前的急性冠状动脉综合征 (ACS) 准则侧重于临床表现. 本综述强调了冠心内成像和生物标志物如何识别ACS内型,以实现个性化治疗和改善结果.
科学领域:
- 心脏病学 心脏病学
- 生物医学科学 生物医学科学
- 翻译医学是一种翻译医学.
背景情况:
- 目前的急性冠状动脉综合征 (ACS) 准则主要依赖于临床表现.
- 斑块破裂和血栓形成是ACS中最被认可的,但不是唯一的,病理生理学途径.
- 新出现的证据需要在传统模型之外更深入地了解ACS病理生理学.
研究的目的:
- 审查冠心内成像和生物标志物的作用,以确定特定的ACS内型.
- 讨论基于已识别的ACS内型的预后影响和定制的管理策略.
- 探索用于非阻塞性冠状动脉心肌梗塞 (MINOCA) 和二次ACS预防的精准医学方法.
主要方法:
- 对冠状动脉内成像技术 (如IVUS,OCT) 和ACS中的生物标志物的当前文献的综述.
- 对调查特定ACS内型与患者结果之间的联系的研究进行分析.
- 综合有关个性化治疗策略的证据,包括抗血栓治疗和再血管化.
- 在MINOCA中检查精准医学的诊断和治疗影响.
主要成果:
- 冠内成像和生物标志物可以识别不同的ACS内型.
- 这些内型具有不同的预后影响,指导个性化管理.
- 精准医学方法为MINOCA和二次ACS预防提供了量身定制的策略.
- 有针对性的干预措施可能会降低某些ACS患者的残留风险.
结论:
- 超越临床表现,了解ACS内型对于最佳的患者护理至关重要.
- 冠内成像和生物标志物是内型识别和风险分层的关键工具.
- 个性化医疗,包括量身定制的抗血栓治疗和MINOCA管理,改善了ACS的结果.
- 有针对性的二次预防策略对于降低ACS患者的残留风险至关重要.
更多相关视频
06:16Signal Acquisition, Score Interpretation, and Economics of a Non-Invasive Point-of-Care Test for Coronary Artery Disease
Published on: August 9, 2024
05:41Left Anterior Descending Coronary Artery Ligation for Ischemia-Reperfusion Research: Model Improvement via Technical Modifications and Quality Control
Published on: December 16, 2022
相关概念视频
Antianginal Drugs: Calcium Channel Blockers and Ranolazine
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
Blood Studies for Cardiovascular System I: Cardiac Biomarkers
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Antianginal Drugs: Nitrates and β-Blockers
Organic nitrates, such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow....
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
